Watanabe, Daichi
Fujii, Hironori
Ohata, Koichi
Iihara, Hirotoshi
Makiyama, Akitaka
Kobayashi, Ryo
Hirose, Chiemi
Hishida, Shiori
Matsuoka, Serika
Tajima, Jesse Yu
Kiyama, Shigeru
Takahashi, Takao
Suzuki, Akio
Matsuhashi, Nobuhisa
Article History
Received: 2 June 2023
Accepted: 6 November 2023
First Online: 8 November 2023
Declarations
:
: The study was conducted in accordance with the Declaration of Helsinki and ethical guidelines for clinical studies. The study followed the guidelines for human studies established by the ethics committee of Gifu University Graduate School of Medicine and approved by the Japanese government (Institutional Review Board Approval No. 2021-A221). Due to the retrospective nature of this study and the anonymity of the presented data, the ethics committee of Gifu University Graduate School of Medicine waived the requirement for obtaining informed consent from the patients whose medical records are included in this study.
: Not applicable.
: H Fujii has received honoraria for lectures from Ono Pharm., Chugai Pharm., and Taiho Pharm.H Iihara has received honoraria for lectures from Taiho Pharm., Chugai Pharma., Yakult Honsha., Astellas Pharma., Eli Lilly and Company., Daiichi Sankyo., AstraZeneca plc, Nippon Kayaku, Ono Pharm., and Nippon Boehringer Ingelheim.K Ohata has received honoraria for lectures from Chugai Pharma. and Nippon Boehringer Ingelheim.C Hirose has received honoraria for lectures from Chugai Pharma., Eli Lilly Japan and Nippon Kayaku.A Makiyama has received honoraria for lectures from Eli Lilly and Company, Taiho Pharm., and Takeda Pharma.T Takahashi has received grants or research funds made to institutions from Yakult Honsha. A Makiyama has received honoraria for lectures from Eli Lilly Japan, Taiho Pharm., and Takeda Pharma.N Matsuhashi has received honoraria for lectures from Asahi Kasei Pharma, Chugai Pharm., Covidien Japan, Daiichi Sankyo, Eli Lilly Japan, Johnson & Johnson, Kaken Pharm., Sanofi, Taiho Pharm., Takeda Pharm., and Yakult Honsha.; grants or research funds made to institution from Abbott, Asahi Kasei Pharma, Chugai Pharm., Covidien Japan, Daiichi Sankyo, Eisai, Eli Lilly Japan, EPâCRSU, EPS Corporation, FUJIFILM, Johnson & Johnson, Kaken Pharm., Kyowa Kirin, MSD, Nippon Kayaku, Ono Pharm., Otsuka Pharm., Sanofi, ShiftZero K.K., Taiho Pharm., Takeda Pharm., Terumo, Tsumura, and Yakult Honsha.A Suzuki has received honoraria for lectures from Toa Eiyo, Asahi Kasei Pharma, Daiichi Sankyo, Pfizer Eisai, Nippon Shinyaku, Celltrion Healthcare Japan, Otsuka Pharm., Sandoz, Daiichi Sankyo, Nipro, Taiho Pharm., Asahi Kasei Pharma, Nippon Chemiphar, Japan Blood Products Organization, Takeda Pharm., and Nippon Boehringer Ingelheim.; and grants made to institution from Nippon Kayaku, Asahi Kasei Pharma, Chugai Pharm., Taiho Pharm., Daiichi Sankyo, Japan Blood Products Organization, Mochida Pharm., and Sun Pharma.The other authors have no conflicts of interest.